Anti-tubercular treatment (ATT) reduces the chances of uveitis recurrence 11-fold
Anti-tubercular treatment (ATT) reduces the chances of uveitis recurrence 11-fold, claims a paper in the British Journal of Ophthalmology.
Professor Soon-Phaik Chee et al., Singapore National Eye Centre, Republic of Singapore, conducted a retrospective review of 182 uveitis patients. Over nine years they were assessed at a single, tertiary institution and completed a minimum of six months follow-up after ATT.
The team measured the clinical characteristics, treatment type, treatment duration and clinical response of each patient. The main outcome measure was the influence of ATT duration on the recurrence of inflammation.
For six months or more 46 patients were administered ATT and 18 patients received ATT for less than six months. Patients who underwent over nine months of ATT were less likely to experience a recurrence in uveitis, compared to patients who did not receive ATT.
Uveitis and latent tuberculosis patients who were administered over nine months of ATT demonstrated an 11-fold decrease in the likelihood of recurrence.